New drug aims to shield cancer patients from chemo side effects
NCT ID NCT07473128
First seen Mar 17, 2026 · Last updated May 20, 2026 · Updated 8 times
Summary
This study tests a drug called trilaciclib in people with limited-stage small cell lung cancer. The goal is to see if it can protect the bone marrow from damage caused by chemotherapy. About 120 participants will receive either trilaciclib or a placebo during their cancer treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LIMITED-STAGE SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.